证券代码：600329 证券简称：达仁堂 公告编号：2025-044 号 津药达仁堂集团股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 表决情况： | | | 1、 公司在任董事9人，出席6人，董事幸建华先生（非独立董事）、董事尚明杰 先生（非独立董事）、独立董事钟铭先生因工作未出席本次会议； 2、 公司在任监事3人，出席1人，监事王远熙先生、监事谢希女士因工作未出席 本次会议； 3、 董事会秘书焦艳女士出席了本次会议；公司首席财务官马健先生、首席制造 官张宇先生出席了本次会议。 | 1、出席会议的股东和代理人人数 | 957 | | --- | --- | | 其中：A 股股东人数 | 931 | | 境外上市外资股股东人数（S 股） | 26 | | 2、出席会议的股东所持有表决权的股份总数（股） | 337,239,879 | | 其中：A 股股东持有股份总数 | 335,036,779 | | 境外 ...

观意字 2025TJ000033 号 致：津药达仁堂集团股份有限公司 北京观韬（天津）律师事务所 关于津药达仁堂集团股份有限公司 2025 年第二次临时股东会的法律意见书 北京观韬（天津）律师事务所（以下简称"本所"）接受津药达仁堂集团股 份有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 年第二次临 时股东会（以下简称"本次股东会"），并依据《中华人民共和国公司法》、《中 华人民共和国证券法》、《上市公司股东大会规则》等有关法律法规、规范性文 件以及《津药达仁堂集团股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，出具本法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得被任何人用于任何 其他目的。本所在此同意，公司可以将本法律意见书作为公司本次股东会的公告 材料，随同其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司 提供的文件和与本次股东会有关的事实进行了核查和验证，现就本次股东会出具 法律意见如下： 一、本次股东会的召集和召开程序 本次股东会由公司董事会根据 2025 年 8 月 13 日召开的 2025 年第五次董事 会 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-043 号 津药达仁堂集团股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 15 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 股东大会召开日期：2025年12月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 15 日 至2025 年 12 月 15 日 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 ...

Core Insights - The 2025 Cardiovascular Health Conference was held in Beijing, attracting nearly 20,000 participants, including leading experts in the cardiovascular field, to discuss public heart health [1][3] - A significant national scientific project, focusing on the "Rapid Rescue Heart Pill" for treating coronary microvascular diseases, was launched during the conference [1][3] Group 1: Clinical Challenges and Research Focus - Coronary microvascular disease is a critical challenge in treating coronary heart disease, with over 30% of patients experiencing inadequate myocardial perfusion despite successful PCI surgery [3] - The new national project aims to address the complexities of microcirculation, shifting clinical focus from merely opening large blood vessels to a dual protection model that includes both large vessels and microcirculation [3][4] Group 2: Integration of Traditional and Modern Medicine - The project will utilize traditional Chinese medicine's holistic approach alongside modern technologies like big data and artificial intelligence to create a dynamic and precise diagnostic and treatment paradigm [4] - The study will center on the "Rapid Rescue Heart Pill," collaborating with top institutions to conduct large-scale, multi-center clinical research adhering to international standards [4][6] Group 3: Strategic Importance for the Company - The involvement in this national project is strategically significant for the company, aiming to meet unmet clinical needs and provide evidence-based treatment options for patients suffering from angina post-PCI [6][8] - The company plans to leverage a rigorous quality control system to ensure the consistency and traceability of trial medications, aiming to clarify the mechanism and clinical value of the "Rapid Rescue Heart Pill" [8] - This initiative represents a key action for the company in implementing the "Healthy China 2030" plan and marks a transition from traditional manufacturing to technology-driven health management [8]

Group 1 - The second China Respiratory Health Conference opened in Guangzhou, focusing on "Collaborative Innovation of Traditional and Western Medicine: Building a New Pattern of Respiratory Health" with over 2,000 experts and scholars in attendance [1] - The "2026 Respiratory Health Community" was established during the opening ceremony, with Tianyao Darentang being one of the first member units [3] - Tianyao Darentang, a traditional Chinese medicine company with a 500-year history, has a product portfolio of 599 drug approvals, including 122 exclusive varieties, covering various health areas [4] Group 2 - In the respiratory product line, Tianyao Darentang has 102 varieties, showcasing key products such as Qingyan Diban and Qingfei Xiaoyan Wan at the conference [5] - The company aims to protect and develop traditional Chinese medicine while promoting respiratory health, focusing on collaboration within the community to enhance innovation [5]

（文章来源：证券日报） 证券日报网讯 12月5日，达仁堂在互动平台回答投资者提问时表示，股东人数信息请关注公司定期报 告。 ...

津药达仁堂集团股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 12 月 15 日 2025 年第二次临时股东大会 文件目录 目 录 现场会议召开时间：2025 年 12 月 15 日下午 2:00 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 | 序号 | 议案 | 页码 | | --- | --- | --- | | 1 | 关于根据新加坡交易所规则对公司现行关联人交易一般性授权进行 修订的议案 | 3 | | 2 | 关于为公司及全体董事、监事、高级管理人员购买责任保险的议案 | 5 | | 3 | 关于修订《公司章程》并办理工商变更的议案 | 7 | | 4 | 关于续聘公司 年度审计师的议案 2025 | 28 | | 5 | 关于公司 2025 年前三季度利润分配预案 | 29 | 2 2025 年第二次临时股东大会 议案一 议案 1：关于根据新加坡交易所规则对公司现行关联人交易一般 性授权进行修订的议案 由于公司经营涵盖中成药品、中药材、生物工程药品、化学原料 药及制剂、营养保健品的生产经营、销售及医疗器械的营销等众多领 ...

Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

Core Viewpoint - Darentang reported significant profit growth in Q3, with strong performance from its fast-acting heart rescue pill [1] Sales Performance - In the first three quarters, the sales revenue of the fast-acting heart rescue pill (including tax) reached 1.716 billion yuan, representing a year-on-year increase of 13.34% [1] - The sales revenue of the throat-soothing pill (including tax) was 376 million yuan, showing a year-on-year growth of 38.61% [1] Strategic Focus - The company is focusing on product and market strategies under brand leadership, enhancing regional coverage and channel penetration [1] - The emphasis on fast-acting products has led to good growth in key categories [1] Future Outlook - The company has streamlined its operations by divesting non-core businesses, which provides ample room for future development in pharmaceutical resource utilization and cost reduction [1] - The performance elasticity is expected to be promising [1] Investment Rating - The company maintains a "Buy" rating based on its strong performance and growth potential [1]

Core Viewpoint - The announcement highlights that Tianjin Yao Daren Tang Group Co., Ltd. has received a drug registration certificate for Loxoprofen Sodium Gel Patch, marking a significant milestone in the company's strategic layout in the transdermal drug delivery field [1][2]. Drug Registration Details - Drug Name: Loxoprofen Sodium Gel Patch - Dosage Form: Patch - Specification: Each patch (14cm×10cm) contains 10g of gel, with 100mg of Loxoprofen Sodium - Registration Category: Class 4 Chemical Drug - Approval Number: National Drug Approval H20255958 - The product is approved for domestic production and meets the relevant drug registration requirements [1][2]. Market Performance and Potential - Loxoprofen Sodium Gel Patch is used for inflammation and pain relief in conditions such as osteoarthritis and muscle pain, and it has been a leading analgesic in the Chinese market [2]. - According to data from the Minai database, the product has maintained a growth rate exceeding double digits in recent years, with projected national sales exceeding 1.7 billion yuan in 2024 and over 980 million yuan in the first half of 2025 [2]. Strategic Development - The company aims to establish a modern traditional Chinese medicine patch technology platform, integrating advanced technology with traditional medicine, and plans to build a product matrix covering chemical drugs, traditional Chinese medicine, and health patches [4]. - The approval of Loxoprofen Sodium Gel Patch signifies that the product has passed the consistency evaluation for generic drugs, although it is not expected to have a significant impact on the company's recent performance [4].